Related Experiment Videos
In vivo and in vitro chemotherapy sensitivity testing for human kidney tumor lines: a comparative study
K H Kurth1, J C Romijn, M Kappendijk
1Department of Urology, Erasmus University Rotterdam, The Netherlands.
Abstract:
In vivo and in vitro chemosensitivity testing has been applied to kidney carcinoma tumor lines. Serially transplantable tumors were implanted subcutaneously in nude mice and the animals were treated with cytostatic drugs. The results of this in vivo assay were compared with the results obtained with the subrenal capsule assay, the DNA precursor assay (3H-thymidine), and the colony-formation assay, utilizing the same tumor line in each case. Higher rates of resistant tumors were found in the in vivo assays than in the in vitro assays. The SRC assay and the DNA assay had the highest predictive value, as judged from comparison with the results obtained with the source tumor (human kidney carcinoma tumor line).
Insights
Comparing in vivo and in vitro chemosensitivity testing for kidney carcinoma revealed higher drug resistance rates in vivo. The subrenal capsule and DNA precursor assays showed the most predictive value for patient outcomes.
Area of Science:
- Oncology
- Translational Research
- Pharmacology
Background:
- Chemosensitivity testing is crucial for optimizing cancer treatment.
- In vivo and in vitro assays offer different approaches to predict drug response.
- Kidney carcinoma presents challenges in selecting effective chemotherapeutic agents.
Purpose of the Study:
- To compare the efficacy of in vivo and in vitro chemosensitivity assays for kidney carcinoma.
- To evaluate the predictive value of different assay methods.
- To identify reliable methods for predicting patient response to cytostatic drugs.
Main Methods:
- Serially transplantable kidney carcinoma tumor lines were implanted subcutaneously in nude mice for in vivo testing.
- Animals were treated with cytostatic drugs to assess tumor response.
- In vitro assays included the subrenal capsule (SRC) assay, DNA precursor (3H-thymidine) assay, and colony-formation assay.
- Results from in vivo assays were compared with in vitro assay outcomes.
Main Results:
- Higher rates of drug-resistant tumors were observed in vivo compared to in vitro assays.
- The SRC assay and the DNA precursor assay demonstrated the highest predictive value.
- Predictive accuracy was determined by comparison with results from the original human kidney carcinoma tumor line.
Conclusions:
- In vivo chemosensitivity assays may provide a more accurate reflection of clinical drug resistance in kidney carcinoma.
- The SRC and DNA precursor assays are promising tools for predicting treatment response.
- Further validation is needed to integrate these findings into clinical practice for kidney carcinoma management.